Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative treatments for infectious diseases, with a primary focus on Clostridium difficile infection (CDI). The company’s lead candidate, ridinilazole, is an orally administered small molecule antibiotic currently undergoing Phase III clinical trials for CDI. Additionally, Summit Therapeutics is advancing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. Founded in 2003 and headquartered in Cambridge, Massachusetts, the company aims to establish new standards of care through its antibiotic development efforts across the United States, Latin America, and Europe.
Discuva is a Cambridge-based company focused on the discovery of next-generation antibiotics to combat drug-resistant bacterial infections. Established to fill significant gaps in the current antibiotic treatment landscape, Discuva utilizes proprietary methods derived from recent advances in genomic technologies. The company aims to develop targeted antibiotics specifically designed to address emerging and highly drug-resistant pathogens, thereby safeguarding public health against the growing threat posed by these infections. With a management team experienced in the pharmaceutical and biotech sectors, Discuva is poised to make substantial contributions to the field of antimicrobial treatment.
DanioLabs
Acquisition in 2007
DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.